drug_type
RELEVANT_DRUG
intervention_type
Adoptive cellular immunotherapy (genetically engineered T cells)
drug_description
Autologous T cells genetically modified to express a CD19-directed CAR with an autocrine p40 cytokine module to enhance activation, expansion, and persistence; administered after lymphodepleting chemotherapy.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-directed chimeric antigen receptor that recognizes CD19 on malignant B cells and triggers T-cell activation and cytolytic killing. An autocrine p40 cytokine module augments activation, expansion, and persistence of the CAR T cells. Administered after lymphodepleting chemotherapy to enhance engraftment and activity.
drug_name
CD19-CAR.p40-T
nct_id_drug_ref
NCT07097207